Eli Lilly granted partial approval for Alzheimer's medication
Eli Lilly’s potential Alzheimer’s drug, Donanemab, received a stamp of approval from a panel of US Food and Drug Administration experts on Monday, Bloomberg News reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.